It is based on enhancing the RFA-induced tumor-killing effect and promoting the remodeling of the tumor immune microenvironment for the sustained effectiveness of RFA therapy, including TAM M1 polarization and CD8+ T cell recruitment to kill tumors. This evidence concerns the gene CD8A and neoplasm.